Annual Cash & Cash Equivalents
$65.22 M
-$128.50 M-66.33%
December 31, 2023
Summary
- As of February 26, 2025, BTAI annual cash & cash equivalents is $65.22 million, with the most recent change of -$128.50 million (-66.33%) on December 31, 2023.
- During the last 3 years, BTAI annual cash & cash equivalents has fallen by -$147.90 million (-69.40%).
- BTAI annual cash & cash equivalents is now -72.00% below its all-time high of $232.97 million, reached on December 31, 2021.
Performance
BTAI Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$40.39 M
-$15.88 M-28.23%
September 30, 2024
Summary
- As of February 26, 2025, BTAI quarterly cash and cash equivalents is $40.39 million, with the most recent change of -$15.88 million (-28.23%) on September 30, 2024.
- Over the past year, BTAI quarterly cash and cash equivalents has stayed the same.
- BTAI quarterly cash and cash equivalents is now -85.21% below its all-time high of $273.06 million, reached on June 30, 2021.
Performance
BTAI Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
BTAI Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -66.3% | 0.0% |
| 3 y3 years | -69.4% | 0.0% |
| 5 y5 years | +53.2% | 0.0% |
BTAI Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -72.0% | at low | -82.7% | at low |
| 5 y | 5-year | -72.0% | +101.1% | -85.2% | +24.6% |
| alltime | all time | -72.0% | -100.0% | -85.2% | +4453.2% |
BioXcel Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $40.39 M(-28.2%) |
| Jun 2024 | - | $56.27 M(-24.1%) |
| Mar 2024 | - | $74.14 M(+13.7%) |
| Dec 2023 | $65.22 M(-66.3%) | $65.22 M(-27.5%) |
| Sep 2023 | - | $89.96 M(-29.5%) |
| Jun 2023 | - | $127.55 M(-22.9%) |
| Mar 2023 | - | $165.52 M(-14.6%) |
| Dec 2022 | $193.72 M(-16.8%) | $193.72 M(-16.6%) |
| Sep 2022 | - | $232.31 M(-0.5%) |
| Jun 2022 | - | $233.45 M(+16.5%) |
| Mar 2022 | - | $200.44 M(-14.0%) |
| Dec 2021 | $232.97 M(+9.3%) | $232.97 M(-7.9%) |
| Sep 2021 | - | $252.91 M(-7.4%) |
| Jun 2021 | - | $273.06 M(+40.7%) |
| Mar 2021 | - | $194.01 M(-9.0%) |
| Dec 2020 | $213.12 M | $213.12 M(-8.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2020 | - | $233.43 M(+256.4%) |
| Jun 2020 | - | $65.50 M(-18.2%) |
| Mar 2020 | - | $80.08 M(+147.0%) |
| Dec 2019 | $32.43 M(-23.8%) | $32.43 M(-19.4%) |
| Sep 2019 | - | $40.25 M(+34.3%) |
| Jun 2019 | - | $29.96 M(-17.4%) |
| Mar 2019 | - | $36.30 M(-14.7%) |
| Dec 2018 | $42.56 M(+4698.8%) | $42.56 M(-9.7%) |
| Sep 2018 | - | $47.12 M(-6.4%) |
| Jun 2018 | - | $50.35 M(-9.2%) |
| Mar 2018 | - | $55.47 M(+6153.1%) |
| Dec 2017 | $887.00 K(>+9900.0%) | $887.00 K |
| Dec 2016 | $0.00(-100.0%) | - |
| Jul 2016 | $348.50 K(+25.9%) | - |
| Jul 2015 | $276.90 K(+406.2%) | - |
| Jul 2014 | $54.70 K | - |
FAQ
- What is BioXcel Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for BioXcel Therapeutics?
- What is BioXcel Therapeutics annual cash & cash equivalents year-on-year change?
- What is BioXcel Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for BioXcel Therapeutics?
- What is BioXcel Therapeutics quarterly cash and cash equivalents year-on-year change?
What is BioXcel Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of BTAI is $65.22 M
What is the all time high annual cash & cash equivalents for BioXcel Therapeutics?
BioXcel Therapeutics all-time high annual cash & cash equivalents is $232.97 M
What is BioXcel Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, BTAI annual cash & cash equivalents has changed by -$128.50 M (-66.33%)
What is BioXcel Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of BTAI is $40.39 M
What is the all time high quarterly cash and cash equivalents for BioXcel Therapeutics?
BioXcel Therapeutics all-time high quarterly cash and cash equivalents is $273.06 M
What is BioXcel Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, BTAI quarterly cash and cash equivalents has changed by $0.00 (0.00%)